Crossmark

Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy

Crossref DOI link: https://doi.org/10.1038/s41551-025-01447-z

Published Online: 2025-07-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Xin https://orcid.org/0000-0002-2173-4201
Le Gall, Camille https://orcid.org/0000-0002-5890-5115
Alexander, Ryan K.

Borgman, Ella https://orcid.org/0009-0005-8570-1686
Balligand, Thomas

Ploegh, Hidde L. https://orcid.org/0000-0002-1090-6071
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI182177)

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (DP1AI150593)

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIH R01AI182177)

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (DP1AI150593)

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (DP1AI150593)

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (DP1AI150593)

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (DP1AI150593)

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (DP1AI150593)
License Information

Text and Data Mining valid from 2025-07-16

Version of Record valid from 2025-07-16
More Information

Article History

Received: 23 July 2024

Accepted: 4 June 2025

First Online: 16 July 2025

Competing interests

: X.L. and H.L.P. have filed a patent covering the technologies described in this publication (international publication number WO2023141500A2). The other authors declare no competing interests.

Document is current

Any future updates will be listed below